157 related articles for article (PubMed ID: 22760495)
1. Effect of specific ADRB1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure: a substudy of the ECHOS trial.
Petersen M; Andersen JT; Jimenez-Solem E; Broedbaek K; Afzal S; Nyegaard M; Børglum AD; Stender S; Torp-Pedersen C; Køber L; Poulsen HE
Pharmacogenet Genomics; 2012 Oct; 22(10):709-15. PubMed ID: 22760495
[TBL] [Abstract][Full Text] [Related]
2. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol.
Sehnert AJ; Daniels SE; Elashoff M; Wingrove JA; Burrow CR; Horne B; Muhlestein JB; Donahue M; Liggett SB; Anderson JL; Kraus WE
J Am Coll Cardiol; 2008 Aug; 52(8):644-51. PubMed ID: 18702968
[TBL] [Abstract][Full Text] [Related]
3. Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients.
Petersen M; Andersen JT; Hjelvang BR; Broedbaek K; Afzal S; Nyegaard M; Børglum AD; Stender S; Køber L; Torp-Pedersen C; Poulsen HE
Br J Clin Pharmacol; 2011 Apr; 71(4):556-65. PubMed ID: 21395649
[TBL] [Abstract][Full Text] [Related]
4. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.
Baudhuin LM; Miller WL; Train L; Bryant S; Hartman KA; Phelps M; Larock M; Jaffe AS
Am J Cardiol; 2010 Aug; 106(3):402-8. PubMed ID: 20643254
[TBL] [Abstract][Full Text] [Related]
5. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.
Sehrt D; Meineke I; Tzvetkov M; Gültepe S; Brockmöller J
Pharmacogenomics; 2011 Jun; 12(6):783-95. PubMed ID: 21599570
[TBL] [Abstract][Full Text] [Related]
6. [Impact of Gly389Arg beta1-adrenoceptor polymorphism on the risk of chronic heart failure, the nature of its course, and on the efficiency of its treatment with carvedilol].
Tepliakov AT; Shilov SN; Berezikova EN; Torim IuIu; Efremov AV; Safronov ID; Maianskaia SD; Popova AA; Voronina EN; Karpov RS
Ter Arkh; 2010; 82(12):22-8. PubMed ID: 21516734
[TBL] [Abstract][Full Text] [Related]
7. Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol.
Chen L; Meyers D; Javorsky G; Burstow D; Lolekha P; Lucas M; Semmler AB; Savarimuthu SM; Fong KM; Yang IA; Atherton J; Galbraith AJ; Parsonage WA; Molenaar P
Pharmacogenet Genomics; 2007 Nov; 17(11):941-9. PubMed ID: 18075464
[TBL] [Abstract][Full Text] [Related]
8. Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET.
Torp-Pedersen C; Poole-Wilson PA; Swedberg K; Cleland JG; Di Lenarda A; Hanrath P; Komajda M; Lutiger B; Metra M; Remme WJ; Scherhag A; Skene A;
Am Heart J; 2005 Feb; 149(2):370-6. PubMed ID: 15846279
[TBL] [Abstract][Full Text] [Related]
9. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of beta-adrenergic antagonists (atenolol, metoprolol tartrate, carvedilol) on the risk of rehospitalization in adults with heart failure.
Go AS; Yang J; Gurwitz JH; Hsu J; Lane K; Platt R
Am J Cardiol; 2007 Aug; 100(4):690-6. PubMed ID: 17697830
[TBL] [Abstract][Full Text] [Related]
11. Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease.
Kubota Y; Asai K; Furuse E; Nakamura S; Murai K; Tsukada YT; Shimizu W
Int J Chron Obstruct Pulmon Dis; 2015; 10():515-23. PubMed ID: 25784798
[TBL] [Abstract][Full Text] [Related]
12. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome.
Lanfear DE; Jones PG; Marsh S; Cresci S; McLeod HL; Spertus JA
JAMA; 2005 Sep; 294(12):1526-33. PubMed ID: 16189366
[TBL] [Abstract][Full Text] [Related]
13. Dose Response of β-Blockers in Adrenergic Receptor Polymorphism Genotypes.
Parikh KS; Fiuzat M; Davis G; Neely M; Blain-Nelson P; Whellan DJ; Abraham WT; Adams KF; Felker GM; Liggett SB; O'Connor CM; Bristow MR
Circ Genom Precis Med; 2018 Aug; 11(8):e002210. PubMed ID: 30354340
[TBL] [Abstract][Full Text] [Related]
14. Death and hospitalization in heart failure patients receiving carvedilol vs. metoprolol tartrate.
Delea TE; Stanford R; Hagiwara M; Edelsberg JS; Oster G
Int J Cardiol; 2005 Mar; 99(1):117-24. PubMed ID: 15721509
[TBL] [Abstract][Full Text] [Related]
15. Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
Fonarow GC; Abraham WT; Albert NM; Stough WG; Gheorghiade M; Greenberg BH; O'Connor CM; Sun JL; Yancy C; Young JB;
Am Heart J; 2007 Jan; 153(1):82.e1-11. PubMed ID: 17174643
[TBL] [Abstract][Full Text] [Related]
16. Carvedilol Compared With Metoprolol Succinate in the Treatment and Prognosis of Patients With Stable Chronic Heart Failure: Carvedilol or Metoprolol Evaluation Study.
Fröhlich H; Zhao J; Täger T; Cebola R; Schellberg D; Katus HA; Grundtvig M; Hole T; Atar D; Agewall S; Frankenstein L
Circ Heart Fail; 2015 Sep; 8(5):887-96. PubMed ID: 26175538
[TBL] [Abstract][Full Text] [Related]
17. Association of common polymorphisms in β1-adrenergic receptor with antihypertensive response to carvedilol.
Si D; Wang J; Xu Y; Chen X; Zhang M; Zhou H
J Cardiovasc Pharmacol; 2014 Oct; 64(4):306-9. PubMed ID: 25291495
[TBL] [Abstract][Full Text] [Related]
18. Effect of carvedilol and metoprolol on the mode of death in patients with heart failure.
Remme WJ; Cleland JG; Erhardt L; Spark P; Torp-Pedersen C; Metra M; Komajda M; Moullet C; Lukas MA; Poole-Wilson P; Di Lenarda A; Swedberg K
Eur J Heart Fail; 2007 Nov; 9(11):1128-35. PubMed ID: 17716943
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics and healthcare outcomes in patients with chronic heart failure.
Kim KM; Murray MD; Tu W; Robarge J; Ding Y; Brater DC; Flockhart DA
Eur J Clin Pharmacol; 2012 Nov; 68(11):1483-91. PubMed ID: 22543981
[TBL] [Abstract][Full Text] [Related]
20. Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure.
Aleong RG; Sauer WH; Robertson AD; Liggett SB; Bristow MR
Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):137-43. PubMed ID: 23275278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
